André P. Boulet, Ph.D. – Chief Scientific Officer

Dr André Boulet has a vast experience in drug development, regulatory affairs, market access, financing and restructuration in the pharmaceutical and biotech fields. A seasoned entrepreneur, he stands out by combining his strengths in applied science, business and finance.

Within Devonian Health Group, he has raised more than $50M in private/public equity, completed phase 1 and phase 2 ulcerative colitis and Atopic Dermatitis clinical programs for the company`s flagship product Thykamine™ as well as a complete line of patented anti-aging products.

Prior to this endeavour, he was a managing partner of SIPAR’s biotech unit, a $400M private investment firm. Prior to SIPAR, Dr Boulet was partner at BioCapital III LP (« BioCapital ») (1996-2002), a Canadian biotech venture capital company.

Throughout his career, Dr Boulet acquired an international expertise in drug development, regulatory affairs and health economics within Hoechst Marion Roussel, Marion Merrell Dow Canada and Laboratoires Nordic (now Sanofi).

Dr Boulet holds a Bachelor’s Degree in Medical Biology from University of Quebec in Trois-Rivieres, a Master’s Degree in experimental medicine/immunology-immunochemistry as well as a PhD in physiology-endocrinology from Laval University in Quebec City. He also did a post-doctorate training at University of Pennsylvania (USA) in biochemistry-biophysics and a training program in Health Economics at York University (UK).


David Baker 1,2, Chairman of the Board of Directors

David is a biotech executive and industry veteran, with over 30 years of experience, in large, mid-size, small, and start-up biopharmaceutical companies. Foundational experience in marketing including the commercialization of five different billion-dollar prescription drug brands in three different therapeutical categories. Broad experience in leadership roles and global general management with specific experience in strategy development/execution, fund raising, investor relations, commercialization, business development/licensing, clinical development, regulatory, manufacturing, and general business operations. Proven track record building, leading, and developing teams.  Extensive experience serving on public and private company and non-profit boards.

Mr. Baker most recently served at President & CEO of Vallon Pharmaceuticals (NASDAQ: VLON), a company he co-founded in 2018 and took public in 2021, before leading the company through a successful reverse merger in 2023.  During his time at Vallon, he built the management team, raised over $30 million, advanced a lead asset from the pre-clinical stage to the late stages of clinical development, and secured a European partnership.

Previously, he was the Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharmaceutical company where he led the merger with Arcturus Therapeutics (NASDAQ: ARCT). Prior to Alcobra, he worked at Shire Plc for 10 years as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing.  He led the commercialization of Adderall XR® and Vyvanse, the two most successful ADHD brands based on annual revenue.

Prior to Shire, he worked at Merck & Co. for over a decade in marketing, sales, market research, and business development. Mr. Baker’s therapeutic expertise includes ADHD, autism, Fragile X Syndrome, osteoporosis, migraine, and hyperlipidemia.


Edouard Dahl 1

Ed Dahl is a retired pharmaceutical executive with over 30 years of highly diversified business experience in three different industries: industrial lighting (GTE Sylvania) consumer packaged goods (Gillette), and pharmaceuticals (Nordic, Marion Merrell Dow, Hoechst Marion Roussel, Aventis, Sanofi and Dermik Labs). His experience at Dermik Labs, a Dermatology company will be especially valuable to Devonian. As GM of the company, he helped grow the Canadian business, quadrupling sales in just 5 years. As Director of Mergers and Acquisitions at Sanofi Canada he completed a $50 million skin care transaction. When retired, he consulted various institutional and private clients in business evaluations.  Ed holds a Bachelor of Commerce from Concordia University in Montreal with a major in economics (1979). In addition, Ed was previously a Chartered Professional Accountant (CPA) and held a Certification in Production and Inventory Control (CPIM).


Jean Forcione 2

Jean Forcione 35-year career has been devoted to the healthcare industry, spanning prescription pharmaceuticals, consumer healthcare, diagnostics, and medical devices.

Jean has held senior executive and board positions at both privately held and publicly traded organizations, including Aventis, Pharmacia, Pfizer, Johnson &Johnson, Phadia, Thermo Fisher Scientific, BBI Group and Orion Biotechnology.

Jean’s focus and expertise revolves around general management, commercialization and M&A. Geographically, he has worked and been responsible for businesses around the globe. In the past 14 years, he has been focused on Private Equity backed businesses, first as an investor/executive and in the last 8 years as an investor, non-executive director, and chairman. During this period, Jean has been closely involved with exits totalling 2.9B € in EV.

Mr. Forcione has a proven track record of building high performance teams and delivering outstanding value creation for shareholders.


Louis Flamand, PhD, MBA – Director 1

Louis Flamand, PhD, MBA, is a full professor and vice-chair of the department of microbiology-infectious-disease-immunology at the Faculty of medicine, Université Laval and senior researcher in the division of infectious and immune diseases at the CHU de Quebec research center. Before joining Laval university, Dr Flamand obtained his PhD at the University of Montreal and post-doctoral training that the National Institutes of Health and at the Institute of Human Virology (Maryland, USA). He received his MBA in pharmaceutical management from Université Laval. Since 2008, he is President of the biohazards risk committee at Université Laval. He is also member of the HHV-6 Foundation scientific advisory board since 2006. Dr Flamand has experience in pre-clinical development. Throughout his career, Dr Flamand has received several competitive scholarship awards and continuous funding support from several funding agencies for his work in virology. Dr Flamand is the author of more than 80 peer-reviewed publications and is lead Editor of the book “Human Herpesviruses HHV-6A, HHV-6B & HHV-7: Diagnosis and Clinical Management” 3rd edition.


Luc Grégoire, President and Chief Executive Officer

Mr. Grégoire is a seasoned strategic executive and board member, with extensive experience in various industries including software, digital media and entertainment, and health sciences. He began his career at Arthur Andersen where he was an international tax partner. He then held various finance and strategic roles at Merck & Co, including CFO of Merck Frosst Canada, progressing to global roles in Merck’s US corporate headquarters.

Mr. Grégoire was most recently the CFO of InforMed Data Services Inc (d/b/a One Drop) (“InfoMed”), a growth stage health tech and medical devices company for diabetes management, backed by Bayer. Effective October 1, 2022, Mr. Gégoire retired from his position as CFO of InfoMed. Prior to InfoMed, Mr. Grégoire was the CFO for DHI Group, Inc. (DHX, NYSE) from November 2016 to January 2021 and AvePoint Inc. (AVPT, NYSE) from October 2014 to October 2016. Prior to AvePoint Inc., Mr. Grégoire held different executive Finance positions at these global public companies: Take Two Interactive Inc, The McGraw Hill Companies and Standard Motor Products Inc.

His career spans over 40 years of experience in accounting, taxation, treasury, financial planning, auditing, merger and acquisition, capital markets and investor relations, corporate governance, as well as international operations and general business management. Through his career, he developed effective and strategic leadership skills and an extensive public and private capital markets outreach strategies, including ongoing interaction with investors, buy and sell-side analysts, capital raises and shareholder activism. Since 2016, Mr. Gregoire has also served on the board of directors of Werber Management Inc., a New York-based residential real estate company. Mr. Grégoire is a CPA-Chartered Accountant, as well as a graduate of Concordia University – B. Comm (1984).

1) Audit Committee member
2) Member of Human Resources Committee